Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

por Karakiewicz, Pierre I, Nott, Louise, Joshi, Abhishek, Kannourakis, George, Tarazi, Jamal, Alam, Mahmood
Publicado 2016

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

por Ueda, Takeshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Tsukamoto, Taiji, Kanayama, Hiroomi, Shinohara, Nobuo, Tarazi, Jamal, Chen, Connie, Kim, Sinil, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Publicado 2013

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

por Qin, Shukui, Bi, Feng, Jin, Jie, Cheng, Ying, Guo, Jun, Ren, Xiubao, Huang, Yiran, Tarazi, Jamal, Tang, Jie, Chen, Connie, Kim, Sinil, Ye, Dingwei
Publicado 2015

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma

por Murphy, Danielle A, Rini, Brian I, Escudier, Bernard, Motzer, Robert J, Wang, Panpan, Li, Sherry, Williams, J Andrew, Tarazi, Jamal C, Martini, Jean-Francois
Publicado 2020

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

por Atkins, Michael B, Gupta, Shilpa, Choueiri, Toni K, McDermott, David F, Puzanov, Igor, Tarazi, Jamal, Keefe, Stephen, Rosbrook, Brad, Chakrabarti, Debasis, Plimack, Elizabeth R
Publicado 2015

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

por Rini, Brian I., Quinn, David I., Baum, Michael, Wood, Laura S., Tarazi, Jamal, Rosbrook, Brad, Arruda, Lillian Shahied, Cisar, Laura, Roberts, W. Gregory, Kim, Sinil, Motzer, Robert J.
Publicado 2014